Skip to content

Enterprise value at other companies

Eli Lilly logo
Eli LillyLLY
$859.77B+10.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$81.42B+18.1%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$3.81B-14.5%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$3.56B+36.6%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$16.77B+178%
Biogen logo
BiogenBIIB
$30.08B+34.9%

Other financials

Income statement

See full
Revenue-
Operating income-$137.4M+5.6%
Net income-$128.4M+3.4%
EPS (diluted)-$0.69+11.5%

Balance sheet

See full
Cash & equivalents$390.7M+551%
Total debt$40.0M-22.3%
Total equity$926.1M-17.5%
Total assets$1.3B-0.4%

Cash flow

See full
Operating cash flow-$131.2M+0.2%
CapEx$2.5M-51.4%
Free cash flow-$133.7M+2.1%

Valuation

See full
Market cap$3.7B+54.2%

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-49.6%+34.2pp
Debt / equity0.0×
Current ratio9.3×-0.3×

Where this comes from

Calculated from Denali Therapeutics Inc.’s reported figures.

The official record: Denali Therapeutics Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Denali Therapeutics Inc.'s enterprise value?
Denali Therapeutics Inc. (DNLI) reported enterprise value of $2.69B in Q1 2026.
How has Denali Therapeutics Inc.'s enterprise value changed year-over-year?
Denali Therapeutics Inc.'s enterprise value increased by 37.1% year-over-year, from $1.97B to $2.69B.
What is the long-term trend for Denali Therapeutics Inc.'s enterprise value?
Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s enterprise value has grown at a -24.4% compound annual growth rate (CAGR), from $9.79B to $2.41B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.